Back to Search
Start Over
Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy
- Source :
- Oncotarget
- Publication Year :
- 2016
- Publisher :
- Impact Journals, LLC, 2016.
-
Abstract
- // Bo Zhang 1, * , Wei Shi 1, * , Ting Jiang 1 , Lanting Wang 2, 3 , Heng Mei 1, 4 , Heng Lu 2 , Yu Hu 1, 4 , Zhiqing Pang 2 1 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, PR China 2 Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai, China 3 School of Medicine, Fudan University, Shanghai, China 4 Collaborative Innovation Center of Hematology, Huazhong University of Science and Technology, China * These authors have contributed equally to this work Correspondence to: Yu Hu, email: dr_huyu@126.com Zhiqing Pang, email: zqpang@fudan.edu.cn Keywords: tumor microenvironment, imatinib mesylate, nanoparticles, micelles, nanomedicine size Received: April 02, 2016 Accepted: August 10, 2016 Published: August 23, 2016 ABSTRACT Effective delivery of nanomedicines to tumor tissues depends on both the tumor microenvironment and nanomedicine properties. Accordingly, tumor microenvironment modification or advanced design of nanomedicine was emerging to improve nanomedicine delivery to tumors. However, few studies have emphasized the necessity to optimize the tumor microenvironment and nanomedicine properties simultaneously to improve tumor treatment. In the present study, imatinib mesylate (IMA) was used to normalize the tumor microenvironment including platelet-derived growth factor receptor-β expression inhibition, tumor vessel normalization, and tumor perfusion improvement as demonstrated by immunofluorescence staining. In addition, the effect of tumor microenvironment normalization on tumor delivery of nanomedicines with different sizes was carefully investigated. It was shown that IMA treatment significantly reduced the accumulation of nanoparticles (NPs) around 110 nm but enhanced the accumulation of micelles around 23 nm by in vivo fluorescence imaging experiment. Furthermore, IMA treatment limited the distribution of NPs inside tumors but increased that of micelles with a more homogeneous pattern. Finally, the anti-tumor efficacy study displayed that IMA pretreatment could significantly increase the therapeutic effects of paclitaxel-loaded micelles. All-together, a new strategy to improve nanomedicine delivery to tumor was provided by optimizing both nanomedicine size and the tumor microenvironment simultaneously, and it will have great potential in clinics for tumor treatment.
- Subjects :
- Male
0301 basic medicine
nanomedicine size
medicine.medical_specialty
Paclitaxel
micelles
Mice, Nude
Antineoplastic Agents
02 engineering and technology
Receptor, Platelet-Derived Growth Factor beta
Mice
03 medical and health sciences
Drug Delivery Systems
Cell Line, Tumor
imatinib mesylate
Internal medicine
Tumor perfusion
Tumor Microenvironment
medicine
Animals
Humans
Mice, Inbred BALB C
Tumor microenvironment
Hematology
Neovascularization, Pathologic
business.industry
Tumor therapy
021001 nanoscience & nanotechnology
Perfusion
Nanomedicine
030104 developmental biology
Imatinib mesylate
Microscopy, Fluorescence
Oncology
Targeted drug delivery
A549 Cells
Immunology
Cancer research
Nanoparticles
Drug Screening Assays, Antitumor
0210 nano-technology
business
Neoplasm Transplantation
Research Paper
Efficacy Study
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....36434d0985e61a37e3ab813651002aa9